Dear Marina Vabistsevits，
I hope this message finds you well. I am a novice in Mendelian randomization and currently reading your work - 'Deciphering how early life adiposity influences breast cancer risk using Mendelian randomization', and it is very intriguing to me. During this process, I have encountered some difficulties in determining the priority of these mediators. I am wondering if you could kindly provide some guidance on the following specific questions:
In Supplementary Table 1 you provided, under the column "Step 1 sensitivity", when only the result for Oestradiol is shown as "NO". However, I believe the results of HOMA-B seem to be similar to it (Supple Data 1 and Data11 you provided).
Similarly, when assessing the sensitivity of step 2, I also find it difficult to reach the same conclusion as you based on the results provided.
Thank you very much for your time and consideration. I look forward to hearing from you at your earliest convenience.
Dear Marina Vabistsevits， I hope this message finds you well. I am a novice in Mendelian randomization and currently reading your work - 'Deciphering how early life adiposity influences breast cancer risk using Mendelian randomization', and it is very intriguing to me. During this process, I have encountered some difficulties in determining the priority of these mediators. I am wondering if you could kindly provide some guidance on the following specific questions:
Thank you very much for your time and consideration. I look forward to hearing from you at your earliest convenience.